{"id":26464,"date":"2012-01-09T13:15:16","date_gmt":"2012-01-09T18:15:16","guid":{"rendered":"http:\/\/countingpips.com\/fx\/2012\/01\/09\/dendreon-jumps-another-10-on-provenge-expectations\/"},"modified":"2012-01-09T13:15:16","modified_gmt":"2012-01-09T18:15:16","slug":"dendreon-jumps-another-10-on-provenge-expectations","status":"publish","type":"post","link":"https:\/\/www.investmacro.com\/fx\/2012\/01\/09\/dendreon-jumps-another-10-on-provenge-expectations\/","title":{"rendered":"Dendreon Jumps Another 10% On Provenge Expectations"},"content":{"rendered":"<p><div id=\"grabDiv1767162\"><object id=\"GrabPlayer1767162\" width=\"540\" height=\"300\" type=\"application\/x-shockwave-flash\" align=\"middle\" data=\"http:\/\/player.grabnetworks.com\/swf\/GrabOSMFPlayer.swf?id=1767162&#038;content=v8dd80ac9aab0e70bac0cbd2f2fa277f18897d2d1&#038;tgt=grabnetworks\"><param name=\"quality\" value=\"high\"\/><param name=\"allowScriptAccess\" value=\"always\"\/><param name=\"allowFullScreen\" value=\"true\"\/><param name=\"menu\" value=\"false\"\/><param name=\"movie\" value=\"http:\/\/player.grabnetworks.com\/swf\/GrabOSMFPlayer.swf?id=1767162&#038;content=v8dd80ac9aab0e70bac0cbd2f2fa277f18897d2d1&#038;tgt=grabnetworks\"\/><\/object><\/div>\n<\/p>\n<p>Shares of Dendreon (NASDAQ:DNDN) are trading 9.5% higher Friday, up for the second consecutive session on optimism on sales of the firm&#8217;s premier and only product Provenge will rise. Revenues from its Provenge drug more than tripled in the fourth quarter to $82 million from the year-ago period. The report eased concerns that had sparked in early August when the company withdrew its 2011 guidance after demand for the drug didn&#8217;t peak as quickly as they projected.<\/p>\n<p><img src='http:\/\/cache.thenewsroom.com\/financial_news_network\/2012\/01\/07\/0_xajkek6c_thumb.jpg' \/><\/p>\n<p><!--post_img[http:\/\/cache.thenewsroom.com\/financial_news_network\/2012\/01\/07\/0_xajkek6c_preview.jpg]--><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Shares of Dendreon (NASDAQ:DNDN) are trading 9.5% higher Friday, up for the second consecutive session on optimism on sales of the firm&#8217;s premier and only product Provenge will rise. Revenues from its Provenge drug more than tripled in the fourth quarter to $82 million from the year-ago period. The report eased concerns that had sparked &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.investmacro.com\/fx\/2012\/01\/09\/dendreon-jumps-another-10-on-provenge-expectations\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Dendreon Jumps Another 10% On Provenge Expectations&#8221;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-26464","post","type-post","status-publish","format-standard","hentry"],"_links":{"self":[{"href":"https:\/\/www.investmacro.com\/fx\/wp-json\/wp\/v2\/posts\/26464","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.investmacro.com\/fx\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.investmacro.com\/fx\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.investmacro.com\/fx\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.investmacro.com\/fx\/wp-json\/wp\/v2\/comments?post=26464"}],"version-history":[{"count":0,"href":"https:\/\/www.investmacro.com\/fx\/wp-json\/wp\/v2\/posts\/26464\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.investmacro.com\/fx\/wp-json\/wp\/v2\/media?parent=26464"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.investmacro.com\/fx\/wp-json\/wp\/v2\/categories?post=26464"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.investmacro.com\/fx\/wp-json\/wp\/v2\/tags?post=26464"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}